UNSPSC 51111716: Rituximab

This classification denotes a monoclonal antibody with the molecular formula C6416H9874N1688O1987S44, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4F4X42SYQ6, more generally known as rituximab. European Medicines Agency schedules rituximab in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12570MIG. The term RITUXIMAB is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 12 no. 1 1998, list 39. Most nations schedule rituximab under HS 30021091 and SITC 54163.

As of Q4 2014, RITUXIMAB remains the US FDA Preferred Term for this commodity. Rituximab bears US NLM identifiers UMLS ID C0732355 and NCI Concept Code C1702. SMILES: CC(=O)NC1C(C(C(OC1N)CO)O)O.

UNSPSC 51111716 Rituximab, a Commodity code, names a monoclonal antibody biopharmaceutical used to treat rheumatoid arthritis, certain lymphomas, and other autoimmune and oncologic conditions. State and local governments procure rituximab primarily through their health systems, Medicaid agencies, and correctional-health programs for eligible patients under formulary coverage. The drug is typically sourced through group purchasing organizations (GPOs), state pharmaceutical contracts, or direct negotiation with manufacturers and specialty distributors; procurement focuses on securing competitive pricing, ensuring reliable supply chain access, and managing prior-authorization protocols across patient populations. Issuing bodies include state departments of health, county hospital systems, municipal health departments, and state Medicaid programs, which consolidate demand across multiple treatment sites and patient populations to achieve volume discounts.

The source provided contains no recent state and local contract opportunities tagged to this code. Without visibility into posted RFPs, RFQs, IBFs, or ITBs, the geographic distribution of current solicitation activity and the timing of near-term awards cannot be determined. Rituximab procurement in the public sector tends to follow established group purchasing agreements and state-negotiated pharmaceutical contracts rather than competitive open solicitations, which may limit the visibility of individual opportunities in standard procurement databases. Business development professionals should monitor state Medicaid RFP activity, group purchasing organization vendor-management cycles, and health-system formulary reviews in their target markets for entry points under this code.